Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation

Abstract Background There is no established standard treatment for acute myeloid leukemia (AML) patients with FLT3 wild-type relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Multi-kinase inhibitor sorafenib has been widely explored in the treatment of AML patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhonghui Jiang, Ya Zhou, Yuxin Bai, Fang Dai, Menglin Fan, Tian Zhang, Danian Nie, Yunxin Zeng, Yirong Jiang, Ping Zhu, Zhiping Fan, Na Xu, Fen Huang, Ren Lin, Min Dai, Xiaojun Xu, Zhangkun Li, Hua Jin, Jing Sun, Qifa Liu, Li Xuan
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Biomarker Research
Subjects:
Sorafenib
Relapse after allogeneic hematopoietic stem cell transplantation
Salvage therapy
FLT3 wide-type
Online Access:https://doi.org/10.1186/s40364-025-00816-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40364-025-00816-9

Similar Items